Obesity and Weight Loss Drug Development Summit on July 14-16, 2025 in Boston, United States

The 3rd Obesity and Weight Loss Drug Development Summit is the place to be for experts in weight loss drug development tackling the obesity epidemic. This year, we're evaluating the obesity landscape, diving deep into the game-changing potential of novel targets and the latest GLP combination therapies to manage side effects and personalise patient treatment.

Hear from the titans of the pharmaceutical industry - Eli Lilly, Novo Nordisk, Boehringer Ingelheim as well as innovative biotechs including, Altimmune, High Tide Therapeutics, and iBio, and many more - as they share their groundbreaking research and strategies for developing more effective, tolerable, and long-lasting weight management solutions.

Obesity rates are increasing, and the pressure is on for real change. Don't miss this pivotal opportunity to network with 70+ obesity scientists and drug development experts forge collaborations, and be part of the solution. The future of weight loss treatment is being written now - be there!

URLs:
Tickets: https://go.evvnt.com/2904709-2?pid=10008
Brochure: https://go.evvnt.com/2904709-3?pid=10008

Time: 8:00 AM - 4:10 PM

Prices:

Industry Pricing - Conference + 3 Workshops / Full Day: USD 4197.00,

Industry Pricing - Conference + 1 Workshop: USD 3398.00,

Industry Pricing - Conference Only: USD 2999.00,

Academic Pricing - Conference + 3 Workshops / Full Day: USD 3597.00,

Academic Pricing - Conference + 1 Workshop: USD 2931.00,

Academic Pricing - Conference Only: USD 2599.00,

Vendor Pricing - Conference + 3 Workshops / Full Day: USD 5097.00,

Vendor Pricing - Conference + 1 Workshop: USD 4166.00,

Vendor Pricing - Conference Only: USD 3699.00

Speakers: Alessandro Pocai, Senior Director - Cardiovascular, Metabolism, PH and Retinal Research, Scientific Strategy and Innovation, Johnson and Johnson, Brandy Bennett, Head Of Obesity Strategy and Business Operations, Regeneron, Charlie Harris, Associate Vice President, Eli Lilly, Evan Frary, Head of Medical Affairs, Zealand, Faraz Naqvi, Medical Director, Ambrosia Biosciences, Hariprasad Vankayalapati, Chief Scientific Officer, Biolexis, Jay Caplan, Founder and President, Fractyl Therapeutics, Jay Olson Biotechnology, Equity Research Analyst, Oppenheimer and Co., Jill Kompa, Senior Global Program Regulatory Director, RA lead Cardiovascular-Metabolism, Novartis, Jingyu Julia Luan, Executive Regulatory Science Director, AstraZeneca, John Suschak, Senior Director, Translational Science, Altimmune, Laurent Audoly, Chief Executive Officer, Prive Bio, Leigh MacConell, Chief Development Officer, High Tide Therapeutics, Linda Sasset, Senior Scientist, RenBio, Mafalda Pereira, Lab Head and Senior Scientist, Boehringer Ingelheim, Martin Brenner, Chief Executive and Chief Scientific Officer, iBio, Rahul Dhanda, Co-Founder and Chief Executive Officer, Syntis Bio, Robert Gabbay, Chief Medical Officer and Senior Vice President at Joslin Diabetes Center and Associate Professor of Medicine, Harvard University, Sharath Hedge, Chief Scientific Officer, Congruence Therapeutics, Steven Dickman, Founder and Chief Executive Officer, CBT Advisors, Teo Uysal, Chief Executive Officer, ERX Pharmaceuticals, Yajing Zhu, Head of Real World Science: Obesity and Liver, Novo Nordisk